GP方案治疗晚期非小细胞肺癌的临床观察

GP regimen for treating advanced non-small cell lung cancer

目的 研究吉西他滨 (健择 ,Gemcitabine ,GEM)与顺铂 (Cisplatin ,PDD)组成的GP方案治疗晚期非小细胞肺癌 (NSCLC)的疗效和毒性反应。方法 19例Ⅲ～Ⅳ期NSCLC患者 ,均经病理组织学和 (或 )细胞学确诊 ,治疗剂量 :GEM 10 0 0～ 12 5 0mg m2 ,静滴第 1、8天 ;DDP 80mg m2 ,静滴第 1天 (或分 3～ 5d给药 ) ,做适当水化利尿 ,2 1d为 1周期 ,2～ 3周期为 1疗程。结果 19例患者中 ,CR 0例 ,PR 9例 ,有效率 4 7.4 % (9 19)。中位缓解期 8.0个月 ,中位生存期 9.6个月。 1年生存率 4 7.4 % (9 19)。最主要的毒副反应为白细胞及血小板降低 ,但均可耐受。结论 GP方案治疗晚期非小细胞肺癌有较高的有效率和较长的生存期 ,毒性可以耐受。

Objective To evaluate the curative and side effects of gemcitabine(GEM) and cisplatin(DDP) regimen for treating advanced non-small cell lung cancer (NSCLC).Methods Nineteen patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received GEM 1000-1250 mg/m2 on d1,8 and DDP 80 mg/m2 on d1 (or divide 3-5days) of 21-day cycle. Curative and side effects were evaluated after two to three cycles were completed.Results Complete remission (CR) was observed in 0 case and PR in 9 cases.The total response rate was 47.4%.The main side effects were leucopenia and thrombasthenia,but they were acceptable.Conclusion The combined regimen of GEM and DDP for treating advanced NSCLC has a high response rate and tolerable side effects.